Efficacy of OK-432 Therapy for the Incisionless Treatment of Head and Neck Cystic Masses: Case series

Hasan, Hesham Yousif Ali; Rizwan, Muhammad A.

doi:10.18295/squmj.2018.18.01.014

Cited by 8 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ogita8 reported the results of OK-432 sclerotherapy in lymphangioma for the first time. In recent years, more and more articles showed OK-432 is a safe and effective treatment modality for lymphatic malformations 9. Kim evaluated 26 cases injected with OK-432 and suggested that the macrocystic type has the best effect and complete aspiration of cystic contents were important factors for success 10.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, more and more articles showed OK-432 is a safe and effective treatment modality for lymphatic malformations. 9 Kim evaluated 26 cases injected with OK-432 and suggested that the macrocystic type has the best effect and complete aspiration of cystic contents were important factors for success. 10 Aluffi Valletti et al also showed a single-center experience to management a series cases of lymphangiomas with surgery or OK-432 sclerotherapy, and they included that OK-432 therapy is a safe and effective option.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

OK-432 Sclerotherapy of Giant Cervicomediastinal Cystic Hygroma

Wang¹,

Li³

et al. 2022

Journal of Craniofacial Surgery

View full text Add to dashboard Cite

Cystic hygroma is one type of the benign malformations and typically located in the neck, clavicle, and others, in children under the age of 5 years. However, the incidence of giant cervicomediastinal giant cystic hygroma is very rare, especially in adulthood. Such a location and age make its diagnosis difficult because they are usually asymptomatic. Complete surgical resection seems impossible while multiple sites are involved. Herein, we present a case of giant cervicomediastinal cystic hygroma, describing the clinical presentation, radiographic features, and OK-432 sclerotherapy. In conclusion, repeated OK-432 sclerotherapy may be an effective treatment option in giant cervicomediastinal cystic hygroma. Pay close attention to patient’s symptoms and vital signs, adjusting the OK-432 dose throughout the process.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

OK-432 Sclerotherapy of Giant Cervicomediastinal Cystic Hygroma

Wang¹,

Li³

et al. 2022

Journal of Craniofacial Surgery

View full text Add to dashboard Cite

show abstract

“…Among the 32 included studies, there were a total of 489 patients with benign cystic lesions. Twenty patients were lost 33 2016 High Hasan 35 2018 High Kim 36 2012 Moderate Miwa 38 2007 High Woo 41 2003 High Wong 45 2017 Moderate Dool 48 2007 Moderate Kusano 50 2020 Moderate Monama 16 2010 High Watanabe 54 2002 High Taguchi 55 2005 Moderate Echavez 18 1994 High Total to follow-up and excluded from analysis, leaving 474 benign cystic lesions in 469 patients, including 5 patients with bilateral lesions. The mean duration of follow-up for all patients was 14.8 months (median, 14 months; range, 4-48 months).…”

Section: Demographicsmentioning

confidence: 99%

Sclerotherapy for Benign Cystic Lesions of the Head and Neck: Systematic Review of 474 Cases

Talmor

Nguyen

Mir

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective The role of sclerotherapy for vascular lesions of the head and neck is well established. However, the efficacy of sclerotherapy for benign cystic lesions of the head and neck is less clear. The objective of this review is to determine the efficacy and safety of sclerotherapy for benign cystic lesions of the head and neck. Data Sources PubMed/MEDLINE, Cochrane Library, and Embase. Review Methods The PRISMA guidelines (Preferred Reporting Systems for Systematic Reviews and Meta-analyses) were followed for this systematic review. Studies of patients with benign head and neck cystic masses treated primarily with sclerotherapy were included. Thirty-two studies met criteria for inclusion. Results A total of 474 cases of sclerotherapy were reviewed. Agents comprised OK-432, ethanol, doxycycline, tetracycline, and bleomycin. Lesions in the analysis were ranula, thyroglossal duct cyst, branchial cleft cyst, benign lymphoepithelial cyst, parotid cyst, thoracic duct cyst, and unspecified lateral neck cyst. A total of 287 patients (60.5%) had a complete response; 132 (27.9%) had a partial response; and 55 (11.6%) had no response. OK-432 was the most widely utilized agent, with a higher rate of complete response than that of ethanol (62.0% vs 39.4%, P = .015). Fifty-three cases (11.2%) required further surgical management. One case of laryngeal edema was reported and managed nonoperatively. Conclusion Sclerotherapy appears to be a safe and efficacious option for benign cystic lesions if malignancy is reliably excluded. Efficacy rates are comparable to those of sclerotherapy for vascular malformations. The rate of serious complications is low, with 1 incident of airway edema reported in the literature.

show abstract

“… 8 , 9 The toxinproducing capacity of the bacterium is eliminated and its anticancer properties are strengthened after exposure to benzylpenicillin and heat treatment. 10 Previous studies have shown that OK-432 is effective in treating patients with various cystic diseases, including ranula, salivary mucocele, auricular hematoma, thyroglossal duct cyst and other diseases. 9 , 11 , 12 , 13 And over the past 30 years, intracapsular sclerotherapy has become the most standard therapy for LMs.…”

Section: Introductionmentioning

confidence: 99%